Opthea Ltd traded at 1.01 this Friday February 3rd, increasing 0.03 or 2.54 percent since the previous trading session. Looking back, over the last four weeks, Opthea Ltd gained 12.22 percent. Over the last 12 months, its price fell by 6.05 percent. Looking ahead, we forecast Opthea Ltd to be priced at 0.91 by the end of this quarter and at 0.84 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
1.01
Daily Change
2.54%
Yearly
-6.05%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Cochlear 221.96 5.06 2.33% 14.00%
CSL 313.81 9.23 3.03% 21.26%
Fisher & Paykel Healthcare 24.34 0.59 2.48% -11.72%
Nanosonics Ltd 4.87 -0.09 -1.81% -3.56%
Paradigm Biopharmaceuticals Ltd 1.50 0.02 1.01% 13.21%
Pacific Edge 0.50 0 0% -54.96%
Pacific Smiles Group Ltd 1.43 -0.01 -0.35% -47.62%
PYC Therapeutics Ltd 0.07 0.001 1.52% -41.74%
Ramsay Health Care 67.16 0.85 1.28% 4.04%
ResMed 32.31 0.31 0.97% -4.12%
Telix Pharmaceuticals Ltd 6.78 -0.10 -1.45% -0.44%


Opthea Ltd
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing novel therapies to treat highly prevalent and progressive retinal eye diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s lead product candidate OPT-302 is in pivotal Phase III clinical trials and being developed for use in combination with anti- Vascular Endothelial Growth Factor (VEGF-A) monotherapies to achieve broader inhibition of the VEGF family. OPT-302 has the potential to address the unmet medical need of wet age-related macular degeneration (AMD) and diabetic macular edema (DME) patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilitating diseases. The Company is advancing the clinical development of OPT-302 in wet AMD and DME clinical trials.